Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer

On July 8, 2026, Ovid Therapeutics Inc. (NASDAQ:OVID) announced respective strategical appointments. Kevin Norrett volition articulation Ovid arsenic main concern serviceman to pb concern and firm improvement functions, arsenic good arsenic strategical partnerships. Most recently, Norrett served arsenic main concern serviceman astatine Soleno Therapeutics.

Ovid besides promoted Charles Carter to CFO, wherever Carter volition pb concern and fiscal operations. Carter succeeds Jeffrey Rona, who volition stay a semipermanent advisor to the institution done 2027. Victoria Fort was promoted to main strategy officer, starring endeavor strategy, capitalist relations, and operational maturation initiatives.

In May, Ovid Therapeutics reported Q1 EPS of (12c), compared with the statement of (11c). CEO Meg Alexander said the archetypal 4th reflected "focused execution" and continued advancement crossed the company's pipeline of tiny molecule medicines for intractable encephalon conditions. Alexander said improvement programs stay connected track, the objective enactment has expanded, and the institution expects to beryllium good capitalized into 2029.

Ovid Therapeutics Inc. (NASDAQ:OVID) develops small-molecule medicines for encephalon disorders, including epilepsies and seizure-related neurological disorders successful the United States.

While we admit the imaginable of OVID arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.